NCT06182124

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

CompletedPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2023-12-20Est. Completion: 2026-05-12

Enrollment target: 1,363 participants

Locations

Alliance for Multispecialty Research, LLC, Doral, Florida, United States
Indago Research & Health Center, Inc, Hialeah, Florida, United States
Clinical Research Atlanta, Stockbridge, Georgia, United States
Optimal Research, Peoria, Illinois, United States
Alliance for Multispecialty Research, LLC, New Orleans, Louisiana, United States
Headlands Research - Detroit, Southfield, Michigan, United States
Rochester Clinical Research, LLC, Rochester, New York, United States
IMA Evaluations, LLC dba IMA Clinical Research, Tarrytown, New York, United States
Accellacare - Wilmington, Wilmington, North Carolina, United States
AMR Clinical, Knoxville, Tennessee, United States
AMR Clinical, Knoxville, Tennessee, United States
Headlands Horizons LLC, Brownsville, Texas, United States
DM Clinical Research- Cyfair, Houston, Texas, United States
Clinical Trials of Texas, LLC dba Flourish Research, San Antonio, Texas, United States
IMA Clinical Research San Antonio, San Antonio, Texas, United States

Sickle Cell Disease (SCD)Invasive Bacterial Infections

Children with sickle cell disease are at high risk of invasive bacterial infections, which may lead to serious complicat…

Argenteuil, FranceEst. completion Jul 15, 2027

Healthy

BEATRIX (group B strEptococcus mATeRnal and Infant VaX study) The purpose of this study is to learn about the safety and…

Birmingham, United StatesEst. completion Nov 6, 2028

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.